Imbio Partners with Heart&Lung Health Ltd to Serve the UK Market with Enhanced Quantitative Imaging Services

April 6, 2021

The company is a leading provider of artificial intelligence (AI) solutions for medical imaging analysis, and Heart&Lung Health, a leading cardiothoracic consultancy firm.

Today they announced their partnership to integrate Imbio AI algorithms within subspecialty radiology workflows to identify lung and cardiac conditions in patients across the United Kingdom.

“We are delighted to integrate the Imbio quantitative imaging technology into our routine practice to augment reporting of CT thorax studies of patients with potential lung diseases. Our interstitial lung disease CT scans may be acquired from numerous institutions that each have various scanners and protocols. Imbio can integrate this into a fluid workflow. Applying innovative technology to our routine clinical practice allows us to deliver rapid, reliable, and uniquely subspecialist imaging reports. This Imbio partnership aligns seamlessly with our mission to bring even more personalized care to patients,” said Heart&Lung Health.

Heart&Lung Health provides specialty radiology services for NHS trusts, private healthcare providers, and academic institutions across the UK. This partnership equips their expert cardiothoracic radiologists with quantitative imaging that provides data-driven insights to benefit patient outcomes. With automated results available upon receipt of the scans, Imbio serves as an aid for CT imaging assessment of cardiothoracic conditions without any additional steps by the radiologist.

“It has been rewarding to see the real-world clinical utilization of Imbio algorithms being realized in the United Kingdom with the Heart&Lung team. Partnering with world class cardiothoracic radiologists is an honor but facilitating an improved efficiency in their workflow for the combined mission of improving patient care is a privilege. Imbio technology will assist Heart&Lung in caring for thoracic patients in the UK,” said Dave Hannes, CEO at Imbio.

Through this partnership, Heart&Lung can further deliver on their vision of accurate and early diagnosis for lung and cardiac conditions where early interventions are key. Imbio can provide invaluable insights that allow Heart&Lung to further advocate on behalf of patients facing chronic lung diseases. By supporting radiology departments with rapid diagnosis and early disease detection, clinicians can facilitate the best treatment plan for their patients.

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.